Injectable semaglutide and tirzepatide created the current market base, but oral GLP-1s, dual agonists, triple agonists, generics, biosimilars and longer-interval dosing could reshape procurement and partnership strategies
Semaglutide, a medication sold under brands such as Ozempic and Wegovy, is a medication that belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists
Dosage: 0.25 to 0.5 mg daily Administration: Subcutaneous injection 1 to 2 inches from lateral epicondyle Frequency: Once daily, some split into twice daily Duration: 4 to 8 weeks for acute injuries, 8 to 12 weeks for chronic Timing: Evening injection may align with natural repair cycles during sleep Starting Conservative Beginning with lower doses and gradually increasing allows you to assess your response while minimizing any potential issues
Safe if prescribed Rybelsus 7 mg Tablet is generally considered safe for heart patients
Even though Wegovy, Ozempic and Mounjaro are not in short supply right now, future shortages aren't off the table
(PubMed) Tangney CC, Tang Y, Evans DA, Morris MC